Sun Pharma Advanced Research News: Shares of Sun Pharma Advanced Research Company nosedived 20 per cent on June 4, 2025 to trade at Rs 156.14 apiece on the NSE. Notably, the stock was locked at its lower circuit limit in early trade. Shares of the pharmaceutical company fell after the company announced the top-line results from the second phase clinical trials of its psoriasis treatment drug.
On June 3, the pharmaceutical company had informed the exchanges about the results of the Phase 2 clinical trials of Vibozilimod (SCD-044), its psoriasis and atopic dermatitis treatment drug. The company mentioned in a release that the drug did not meet the goal of 75 per cent improvement in PASI (Psoriasis Area and Severity Index) score during the Phase 2 trials.
“....announced the top-line results from the Phase 2 clinical trials evaluating Vibozilimod (SCD-044) for the treatment of moderate-to-severe Psoriasis (SOLARES PsO) and Atopic Dermatitis (SOLARES AD). SPIL informed that both SOLARES PsO and SOLARES AD studies did not meet the primary endpoint of 75 per cent improvement in PASI (Psoriasis Area and Severity Index) score (> PASI75) at Week 16 and 75 per cent improvement in EASI (Eczema Area and Severity Index) score (>EASI75) at Week 16 respectively,” the company said in a filing.
The stock declined as D-Street factored in the impact of the announcement by the pharma company. The company mentioned in the release that both SPARC and SPIL will evaluate the appropriate next steps for SCD-044.
SPARC Q4 Results
Sun Pharmaceutical Advanced Research’s consolidated revenue from operations grew by over 64 per cent to Rs 27.19 crore in the March quarter of FY 2024-25 compared to Rs 16.56 crore in the corresponding quarter of the previous year. The consolidated loss-after-tax of the company for the March quarter of FY 25 narrowed to Rs 59.77 crore compared to Rs 105.79 crore in the March quarter of FY 24. Its consolidated revenue from operations declined by 5 per cent to Rs 71.77 crore compared to Rs 75.55 crore in the preceding fiscal. The consolidated loss-after-tax for FY 2024-25 narrowed to Rs 342.51 crore compared to Rs 387.21 crore in the preceding fiscal.
SPARC Share Price History
Shares of Sun Pharma Advanced Research Company have traded with a downward trend. Shares of the pharma company have tumbled over 22 per cent on the NSE. On a year-to-date (YTD) basis, the stock has slipped nearly 20 per cent. Over the last six months, shares of the pharma company have declined by over 26 percent.
At the time of writing, shares of Sun Pharmaceutical Advanced Research Company were trading at Rs 160.26 apiece on the NSE, down by 17.89 per cent.
